55
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice

&
Pages 47-54 | Published online: 10 Jan 2013

References

  • PoppJArltSPharmacological treatment of dementia and mild cognitive impairment due to Alzheimer’s diseaseCurr Opin Psychiatry20112455656121934621
  • FarlowMRGrossbergGTMengXOlinJSomogyiMRivastigmine transdermal patch and capsule in Alzheimer’s disease: influence of disease stage on response to therapyInt J Geriatr Psychiatry2011261236124322068922
  • LeeJHSevignyJEffects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer diseaseAlzheimer Dis Assoc Disord201125586220975519
  • GauthierSJubyARehelBSchecterREXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer’s diseaseInt J Clin Pract20076188689517504350
  • WinbladBMachadoJCUse of rivastigmine transdermal patch in the treatment of Alzheimer’s diseaseExpert Opin Drug Deliv200851377138619040398
  • CummingsJWinbladBA rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementiaExpert Rev Neurother200771457146317997695
  • MolinuevoJLArranzFJImpact of transdermal drug delivery on treatment adherence in patients with Alzheimer’s diseaseExpert Rev Neurother201212313722243044
  • MolinuevoJLArranzFJAssessment of the strategies to improve therapeutic compliance in routine clinical practice in noncompliant patients with Alzheimer-type dementiaRev Neurol201254657322234564
  • BlesaRBallardCOrgogozoJMLaneRThomasSKCaregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer diseaseNeurology2007694 Suppl 1S23S2817646620
  • SevillaCJiménez-CaballeroPEAlfonsoVOrally disintegrating donepezil: are the main caregivers of patients with Alzheimer’s disease more satisfied with this formulation of donepezil than with the traditional one?Rev Neurol20094945145719859884
  • CummingsJFroelichLBlackSERandomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 versus 10 cm2) in Alzheimer’s diseaseDement Geriatr Cogn Disord20123334135322796905
  • BullockRTouchonJBergmanHRivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year periodCurr Med Res Opin2005211317132716083542
  • LockhartIAMitchellSAKellySSafety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer’s disease: systematic review of the ‘real-world’ evidenceDement Geriatr Cogn Disord20092838940319893314
  • WinbladBCummingsJAndreasenNA six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsuleInt J Geriatr Psychiatry20072245646717380489
  • GuayDRRivastigmine transdermal patch: role in the management of Alzheimer’s diseaseConsult Pharm20082359860919032006
  • MonodSRochatSGoldGBülaCReview in geriatric medicineRev Med Suisse200951924 French19216320
  • BassilNGrossbergGTNovel regimens and delivery systems in the pharmacological treatment of Alzheimer’s diseaseCNS Drugs20092329330719374459